FDC Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
February 09, 2023 at 06:46 am EST
Share
FDC Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 4,092.97 million compared to INR 3,417.81 million a year ago. Revenue was INR 4,277.06 million compared to INR 3,546.25 million a year ago. Net income was INR 407.47 million compared to INR 356.92 million a year ago. Basic earnings per share from continuing operations was INR 2.45 compared to INR 2.11 a year ago.
For the nine months, sales was INR 13,489.47 million compared to INR 11,868.69 million a year ago. Revenue was INR 13,992.08 million compared to INR 12,532.94 million a year ago. Net income was INR 1,633.25 million compared to INR 2,059.59 million a year ago. Basic earnings per share from continuing operations was INR 9.81 compared to INR 12.19 a year ago.
FDC Limited is an India-based company, which is principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations, and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
FDC LIMITED 
